Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
| Revenue (TTM) | $4.72B |
| Gross Profit (TTM) | $4.30B |
| EBITDA | $2.01B |
| Operating Margin | 30.20% |
| Return on Equity | 5.05% |
| Return on Assets | 6.92% |
| Revenue/Share (TTM) | $75.24 |
| Book Value | $65.39 |
| Price-to-Book | 3.48 |
| Price-to-Sales (TTM) | 3.19 |
| EV/Revenue | 3.682 |
| EV/EBITDA | 15.16 |
| Quarterly Earnings Growth (YoY) | 3.20% |
| Quarterly Revenue Growth (YoY) | 10.40% |
| Shares Outstanding | $64.19M |
| Float | $62.29M |
| % Insiders | 2.93% |
| % Institutions | 103.31% |
Volatility is currently expanding
Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.
Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
Jazz Pharmaceuticals NASDAQ: JAZZ reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset product-specific pressures and continued investment in its pipeline.
– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – – Company raises full year 2026 total revenue guidance – – Ziihera® launched in HER2+ 1L mGEA – – Xywav® revenues grew 12% YoY with 425 net patient adds in 3Q26 – – Closed Actio acquisition, adding ABS-1230 (JZP6979) to rare epilepsy portfolio – DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2026 (3Q26). "Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.
Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare brain cancers For U.S. media and investors only DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that clinical and preclinical research from its neuro-oncology portfolio will be presented at the upcoming 2026 Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 12-15 in Philadelphia. Key highlights include: The confirmatory Phase 3 ACTION trial evaluating Modeyso® (dordaviprone), formerly ONC201, continues to advance.
Jazz Pharmaceuticals' financial results are improving. The company's oncology business could push sales and earnings even higher.
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy delivered statistically significant and clinically meaningful OS benefit, reducing the risk of death by 24% versus trastuzumab plus chemotherapy For U.S. media and investors only DUBLIN, Oct. 23, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without Tevimbra® (tislelizumab-jsgr), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results from the second interim, and final formal, analysis were presented as a late-breaking rapid oral presentation (LBA79) at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on JAZZ and any ticker you trade — then tracks every position and per-strategy win rate.
